cachexia

Summary

Summary: General ill health, malnutrition, and weight loss, usually associated with chronic disease.

Top Publications

  1. Fujitsuka N, Asakawa A, Uezono Y, Minami K, Yamaguchi T, Niijima A, et al. Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival. Transl Psychiatry. 2011;1:e23 pubmed publisher
    Cancer anorexia-cachexia syndrome is characterized by decreased food intake, weight loss, muscle tissue wasting and psychological distress, and this syndrome is a major source of increased morbidity and mortality in cancer patients...
  2. Tsoli M, Robertson G. Cancer cachexia: malignant inflammation, tumorkines, and metabolic mayhem. Trends Endocrinol Metab. 2013;24:174-83 pubmed publisher
    b>Cachexia has a devastating impact on survival and quality of life for many cancer patients...
  3. Murphy K, Chee A, Gleeson B, Naim T, Swiderski K, Koopman R, et al. Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice. Am J Physiol Regul Integr Comp Physiol. 2011;301:R716-26 pubmed publisher
    Cancer cachexia describes the progressive skeletal muscle wasting and weakness in many cancer patients and accounts for >20% of cancer-related deaths...
  4. Tan B, Ross J, Kaasa S, Skorpen F, Fearon K. Identification of possible genetic polymorphisms involved in cancer cachexia: a systematic review. J Genet. 2011;90:165-77 pubmed
    Cancer cachexia is a polygenic and complex syndrome...
  5. Blum D, Strasser F. Cachexia assessment tools. Curr Opin Support Palliat Care. 2011;5:350-5 pubmed publisher
    b>Cachexia is a common negative consequence of cancer and is often unrecognized. To assess cachexia, malnutrition assessment tools are used...
  6. Valentová M, von Haehling S, Krause C, Ebner N, Steinbeck L, Cramer L, et al. Cardiac cachexia is associated with right ventricular failure and liver dysfunction. Int J Cardiol. 2013;169:219-24 pubmed publisher
    The mechanisms involved in cardiac cachexia remain poorly understood. We examined the association of right ventricular (RV) and hepatic dysfunction with cardiac cachexia.
  7. Hall D, Ma J, Marco S, Gallouzi I. Inducible nitric oxide synthase (iNOS) in muscle wasting syndrome, sarcopenia, and cachexia. Aging (Albany NY). 2011;3:702-15 pubmed
    ..with age (sarcopenia) or rapidly appears at the late stages of deadly diseases such as cancer, AIDS, and sepsis (cachexia)...
  8. Tuca A, Jiménez Fonseca P, Gascon P. Clinical evaluation and optimal management of cancer cachexia. Crit Rev Oncol Hematol. 2013;88:625-36 pubmed publisher
    Cancer anorexia-cachexia syndrome (CACS) is a complex metabolic syndrome, different from malnutrition and sarcopenia, which is very common in cancer patients...
  9. Das S, Hoefler G. The role of triglyceride lipases in cancer associated cachexia. Trends Mol Med. 2013;19:292-301 pubmed publisher
    Cancer associated cachexia (CAC) is a complex multiorgan syndrome frequently associated with various forms of cancer. Affected patients suffer from a dramatic loss of skeletal muscle and adipose tissue...

Scientific Experts

More Information

Publications62

  1. Tan B, Fladvad T, Braun T, Vigano A, Strasser F, Deans D, et al. P-selectin genotype is associated with the development of cancer cachexia. EMBO Mol Med. 2012;4:462-71 pubmed publisher
    The variable predisposition to cachexia may, in part, be due to the interaction of host genotype...
  2. Maccio A, Madeddu C, Mantovani G. Current pharmacotherapy options for cancer anorexia and cachexia. Expert Opin Pharmacother. 2012;13:2453-72 pubmed publisher
    Anorexia and cachexia syndrome represents a complex clinical picture that occurs in the late stage of several chronic inflammatory diseases, including cancer...
  3. Bonetto A, Aydogdu T, Jin X, Zhang Z, Zhan R, Puzis L, et al. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab. 2012;303:E410-21 pubmed publisher
    b>Cachexia, the metabolic dysregulation leading to sustained loss of muscle and adipose tissue, is a devastating complication of cancer and other chronic diseases...
  4. Lourenço A, Vasques Nóvoa F, Fontoura D, Bras Silva C, Roncon Albuquerque R, Leite Moreira A. A Western-type diet attenuates pulmonary hypertension with heart failure and cardiac cachexia in rats. J Nutr. 2011;141:1954-60 pubmed publisher
    ..diets (WD) constitute risk factors for disease but may have distinct effects in heart failure (HF) with cardiac cachexia (CC)...
  5. Solheim T, Fayers P, Fladvad T, Tan B, Skorpen F, Fearon K, et al. Is there a genetic cause for cancer cachexia? - a clinical validation study in 1797 patients. Br J Cancer. 2011;105:1244-51 pubmed publisher
    b>Cachexia has major impact on cancer patients' morbidity and mortality. Future development of cachexia treatment needs methods for early identification of patients at risk...
  6. Cheng K, Li Y, Cheng J. The use of herbal medicine in cancer-related anorexia/ cachexia treatment around the world. Curr Pharm Des. 2012;18:4819-26 pubmed
    Cancer-related cachexia, a condition in which the body is consumed by deranged carbohydrate, lipid and protein metabolism that is induced by inflammatory cytokines...
  7. Tran E, Chinnasamy D, Yu Z, Morgan R, Lee C, Restifo N, et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med. 2013;210:1125-35 pubmed publisher
    ..into mice bearing a variety of subcutaneous tumors mediated limited antitumor effects and induced significant cachexia and lethal bone toxicities in two mouse strains...
  8. Del Fabbro E, Hui D, Dalal S, Dev R, Nooruddin Z, Noorhuddin Z, et al. Clinical outcomes and contributors to weight loss in a cancer cachexia clinic. J Palliat Med. 2011;14:1004-8 pubmed publisher
    Cancer cachexia is considered intractable, with few therapeutic options. Secondary nutrition impact symptoms (S-NIS) such as nausea may further contribute to weight loss by decreasing nutrient intake...
  9. Zastrow A, Wolf J, Giannitsis E, Katus H, Herzog W, Friederich H, et al. Elevated myocardial enzymes and natriuretic peptides in anorexia nervosa: prototypic condition for the pathophysiology of cachexia?. Cardiology. 2011;118:256-9 pubmed publisher
    ..high myocardial enzymes and NT-proBNP in cachectic anorectic patients might resemble conditions of cardiac cachexia. A review of the available literature is provided...
  10. Chen J, Walton K, Winbanks C, Murphy K, Thomson R, Makanji Y, et al. Elevated expression of activins promotes muscle wasting and cachexia. FASEB J. 2014;28:1711-23 pubmed publisher
    In models of cancer cachexia, inhibiting type IIB activin receptors (ActRIIBs) reverse muscle wasting and prolongs survival, even with continued tumor growth...
  11. Chung T, Yen Ping Kuo M, Chen J, Huang D. YC-1 rescues cancer cachexia by affecting lipolysis and adipogenesis. Int J Cancer. 2011;129:2274-83 pubmed publisher
    ..due to increased lipolysis but also to an impairment of adipogenesis, is a key feature of weight loss in cancer cachexia. Because of the myriad pathogenic signaling pathways essential for atrophy of adipose tissue, effective ..
  12. Del Fabbro E, Dev R, Hui D, Palmer L, Bruera E. Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. J Clin Oncol. 2013;31:1271-6 pubmed publisher
    ..These studies were limited by a lack of blinding and absence of placebo controls. The primary purpose of this study was to compare melatonin with placebo for appetite improvement in patients with cancer cachexia.
  13. Muscaritoli M, Lucia S, Molfino A, Cederholm T, Rossi Fanelli F. Muscle atrophy in aging and chronic diseases: is it sarcopenia or cachexia?. Intern Emerg Med. 2013;8:553-60 pubmed publisher
    b>Cachexia and sarcopenia present several analogies in both the pathogenic mechanisms and the clinical picture. The loss of muscle mass and strength is a hallmark of these two clinical conditions...
  14. Martínez Hernández P, Hernanz Macías Á, Gómez Candela C, Grande Aragón C, Feliú Batlle J, Castro Carpeño J, et al. Serum interleukin-15 levels in cancer patients with cachexia. Oncol Rep. 2012;28:1443-52 pubmed publisher
    ..The role of IL-15 in human cancer cachexia is unknown...
  15. Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol. 2013;10:90-9 pubmed publisher
    Cancer cachexia is a metabolic syndrome that can be present even in the absence of weight loss ('precachexia'). Cachexia is often compounded by pre-existing muscle loss, and is exacerbated by cancer therapy...
  16. Paul P, Kumar A. TRAF6 coordinates the activation of autophagy and ubiquitin-proteasome systems in atrophying skeletal muscle. Autophagy. 2011;7:555-6 pubmed
    ..Muscle-specific depletion of TRAF6 preserves skeletal muscle mass in a mouse model of cancer cachexia or denervation...
  17. Velazquez K, Enos R, Narsale A, Puppa M, Davis J, Murphy E, et al. Quercetin supplementation attenuates the progression of cancer cachexia in ApcMin/+ mice. J Nutr. 2014;144:868-75 pubmed publisher
    Although there are currently no approved treatments for cancer cachexia, there is an intensified interest in developing therapies because of the high mortality index associated with muscle wasting diseases...
  18. Op den Kamp C, Langen R, Minnaard R, Kelders M, Snepvangers F, Hesselink M, et al. Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system. Lung Cancer. 2012;76:112-7 pubmed publisher
    b>Cachexia is a prevalent phenomenon of non-small cell lung cancer (NSCLC) which is responsible for increased mortality and deterioration of physical performance...
  19. Springer J, Tschirner A, Hartman K, Palus S, Wirth E, Ruis S, et al. Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia. Int J Cancer. 2012;131:2187-96 pubmed publisher
    b>Cachexia is a common co-morbidity in cancer occurring in up to 80% of patients depending on the type of cancer...
  20. Scheede Bergdahl C, Watt H, Trutschnigg B, Kilgour R, Haggarty A, Lucar E, et al. Is IL-6 the best pro-inflammatory biomarker of clinical outcomes of cancer cachexia?. Clin Nutr. 2012;31:85-8 pubmed publisher
    Despite the descriptive presence of cancer cachexia (CC) in clinical practice, the underlying mechanisms and diagnostic definition have not been clearly identified...
  21. Oberholzer R, Hopkinson J, Baumann K, Omlin A, Kaasa S, Fearon K, et al. Psychosocial effects of cancer cachexia: a systematic literature search and qualitative analysis. J Pain Symptom Manage. 2013;46:77-95 pubmed publisher
    Cancer cachexia is debilitating and affects most patients with advanced cancer. Because treatment options are poor, the psychosocial effects of cancer cachexia always should be assessed and psychosocial support provided.
  22. Castillo Martinez L, Colín Ramírez E, Orea Tejeda A, González Islas D, Rodríguez García W, Santillán Díaz C, et al. Cachexia assessed by bioimpedance vector analysis as a prognostic indicator in chronic stable heart failure patients. Nutrition. 2012;28:886-91 pubmed publisher
    ..This study explored whether the cachectic state assessed by bioimpedance vector analysis provides additional prognostic information about mortality from all causes...
  23. Fujitsuka N, Asakawa A, Amitani H, Hattori T, Inui A. Efficacy of ghrelin in cancer cachexia: clinical trials and a novel treatment by rikkunshito. Crit Rev Oncog. 2012;17:277-84 pubmed
    b>Cachexia is characterized by decreased food intake, increased energy expenditure, and muscle wasting...
  24. Dumas J, Peyta L, Couet C, Servais S. Implication of liver cardiolipins in mitochondrial energy metabolism disorder in cancer cachexia. Biochimie. 2013;95:27-32 pubmed publisher
    ..Cancer cachexia is a complex and dynamic process characterized by a negative energy balance induced by anorexia and ..
  25. Suzuki H, Asakawa A, Amitani H, Nakamura N, Inui A. Cancer cachexia--pathophysiology and management. J Gastroenterol. 2013;48:574-94 pubmed publisher
    About half of all cancer patients show a syndrome of cachexia, characterized by anorexia and loss of adipose tissue and skeletal muscle mass...
  26. Garcia J, Friend J, Allen S. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer. 2013;21:129-37 pubmed publisher
    b>Cachexia in cancer adversely affects patients' perception of symptoms, well-being, and response to therapy, and shortens survival...
  27. Di Marco S, Cammas A, Lian X, Kovacs E, Ma J, Hall D, et al. The translation inhibitor pateamine A prevents cachexia-induced muscle wasting in mice. Nat Commun. 2012;3:896 pubmed publisher
    b>Cachexia, or muscle-wasting syndrome, is one of the major causes of death in patients affected by diseases such as cancer, AIDS and sepsis. However, no effective anti-cachectic treatment is currently available...
  28. Wang H, Lai Y, Chan Y, Li T, Wu C. Epigallocatechin-3-gallate effectively attenuates skeletal muscle atrophy caused by cancer cachexia. Cancer Lett. 2011;305:40-9 pubmed publisher
    b>Cachexia, also known as wasting syndrome notably with skeletal muscle atrophy, costs nearly one-third of all cancer deaths in man...
  29. Imoto A, Mitsunaga S, Inagaki M, Aoyagi K, Sasaki H, Ikeda M, et al. Neural invasion induces cachexia via astrocytic activation of neural route in pancreatic cancer. Int J Cancer. 2012;131:2795-807 pubmed publisher
    Pancreatic cancer is characterized by a high frequency of cachexia, pain and neural invasion (N-inv). Neural damage is occurred by N-inv and modulates pain and muscle atrophy via the activation of astrocyte in the connected spine...
  30. Kanat O, Cubukcu E, Avci N, Budak F, Ercan I, Canhoroz M, et al. Comparison of three different treatment modalities in the management of cancer cachexia. Tumori. 2013;99:229-33 pubmed publisher
    The optimal treatment of cancer cachexia remains unknown. In this study, we compared the efficacy of three different treatment modalities in the management of cancer cachexia.
  31. Laviano A, Seelaender M, Sanchez Lara K, Gioulbasanis I, Molfino A, Rossi Fanelli F. Beyond anorexia -cachexia. Nutrition and modulation of cancer patients' metabolism: supplementary, complementary or alternative anti-neoplastic therapy?. Eur J Pharmacol. 2011;668 Suppl 1:S87-90 pubmed publisher
    ..to be a key factor determining the cancer-associated biochemical abnormalities eventually leading to anorexia and cachexia. Interestingly, inflammation is also involved in carcinogenesis, cancer progression and metastasis by impairing ..
  32. Khamoui A, Kim J. Candidate mechanisms underlying effects of contractile activity on muscle morphology and energetics in cancer cachexia. Eur J Cancer Care (Engl). 2012;21:143-57 pubmed publisher
    Skeletal muscle wasting is a prominent pathophysiological feature of cancer cachexia. Recent evidence suggests the manifestation of mitochondrial dysfunction along with a diminished oxidative capacity...
  33. Gioulbasanis I, Georgoulias P, Vlachostergios P, Baracos V, Ghosh S, Giannousi Z, et al. Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: interrelations and associations with prognosis. Lung Cancer. 2011;74:516-20 pubmed publisher
    Lung cancer patients frequently present with weight loss in the context of the cachexia syndrome. Despite its high clinical significance, definite diagnostic criteria of cachexia are lacking...
  34. Lima M, Sato S, Enos R, Baynes J, Carson J. Development of an UPLC mass spectrometry method for measurement of myofibrillar protein synthesis: application to analysis of murine muscles during cancer cachexia. J Appl Physiol (1985). 2013;114:824-8 pubmed publisher
    b>Cachexia, characterized by skeletal muscle mass loss, is a major contributory factor to patient morbidity and mortality during cancer...
  35. Reed S, Sandesara P, Senf S, Judge A. Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy. FASEB J. 2012;26:987-1000 pubmed publisher
    b>Cachexia is characterized by inexorable muscle wasting that significantly affects patient prognosis and increases mortality. Therefore, understanding the molecular basis of this muscle wasting is of significant importance...
  36. Reid J, Mills M, Cantwell M, Cardwell C, Murray L, Donnelly M. Thalidomide for managing cancer cachexia. Cochrane Database Syst Rev. 2012;:CD008664 pubmed publisher
    Cancer cachexia is a multidimensional syndrome characterised by wasting, loss of weight, loss of appetite, metabolic alterations, fatigue and reduced performance status...
  37. Robert F, Mills J, Agenor A, Wang D, Dimarco S, Cencic R, et al. Targeting protein synthesis in a Myc/mTOR-driven model of anorexia-cachexia syndrome delays its onset and prolongs survival. Cancer Res. 2012;72:747-56 pubmed publisher
    Anorexia-cachexia syndrome (ACS) is a major determinant of cancer-related death that causes progressive body weight loss due to depletion of skeletal muscle mass and body fat...
  38. Naito T, Tashiro M, Yamamoto K, Ohnishi K, Kagawa Y, Kawakami J. Impact of cachexia on pharmacokinetic disposition of and clinical responses to oxycodone in cancer patients. Eur J Clin Pharmacol. 2012;68:1411-8 pubmed publisher
    Cancer cachexia is characterized by hypoalbuminemia and with the hepatic production of acute-phase proteins in response to malignant growth...
  39. Fearon K, Glass D, Guttridge D. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012;16:153-66 pubmed publisher
    Cancer cachexia is characterized by a significant reduction in body weight resulting predominantly from loss of adipose tissue and skeletal muscle...
  40. Muliawati Y, Haroen H, Rotty L. Cancer anorexia - cachexia syndrome. Acta Med Indones. 2012;44:154-62 pubmed
    Cancer anorexia-cachexia syndrome (CACS) is a devastating and debilitating aspect at any stage of malignancy. It presents primarily as anorexia, weight loss and muscle wasting secondary to inadequate oral intake and metabolic changes...
  41. Asp M, Tian M, Kliewer K, Belury M. Rosiglitazone delayed weight loss and anorexia while attenuating adipose depletion in mice with cancer cachexia. Cancer Biol Ther. 2011;12:957-65 pubmed publisher
    b>Cachexia is characterized by severe weight loss, including adipose and muscle wasting, and occurs in a large percentage of cancer patients...
  42. Burney B, Hayes T, Smiechowska J, Cardwell G, Papusha V, Bhargava P, et al. Low testosterone levels and increased inflammatory markers in patients with cancer and relationship with cachexia. J Clin Endocrinol Metab. 2012;97:E700-9 pubmed publisher
    ..These symptoms are seen in men with hypogonadism and/or inflammatory conditions. However, the relative contribution of testosterone and inflammation to symptom burden in cancer has not been well-established...
  43. Cuenca A, Cuenca A, Winfield R, Joiner D, Gentile L, Delano M, et al. Novel role for tumor-induced expansion of myeloid-derived cells in cancer cachexia. J Immunol. 2014;192:6111-9 pubmed publisher
    Cancer progression is associated with inflammation, increased metabolic demand, infection, cachexia, and eventually death...
  44. Murphy K, Chee A, Trieu J, Naim T, Lynch G. Importance of functional and metabolic impairments in the characterization of the C-26 murine model of cancer cachexia. Dis Model Mech. 2012;5:533-45 pubmed publisher
    Cancer cachexia describes the progressive skeletal muscle wasting and weakness that is associated with many cancers. It impairs quality of life and accounts for >20% of all cancer-related deaths...
  45. Argiles J, Busquets S, Lopez Soriano F. Anti-inflammatory therapies in cancer cachexia. Eur J Pharmacol. 2011;668 Suppl 1:S81-6 pubmed publisher
    ..and neurons, where they produce a complex cascade of biological responses leading to the wasting associated with cachexia. The cytokines that have been involved in this cachectic response are TNF-alpha, IL-1, IL-6 and interferon-gamma...
  46. Op den Kamp C, Langen R, Snepvangers F, de Theije C, Schellekens J, Laugs F, et al. Nuclear transcription factor ? B activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia. Am J Clin Nutr. 2013;98:738-48 pubmed publisher
    Experimental models of cancer cachexia have indicated that systemic inflammation induces muscle-protein breakdown and wasting via muscular nuclear transcription factor ?B (NF-?B) activation...
  47. Braun T, Grossberg A, Krasnow S, Levasseur P, Szumowski M, Zhu X, et al. Cancer- and endotoxin-induced cachexia require intact glucocorticoid signaling in skeletal muscle. FASEB J. 2013;27:3572-82 pubmed publisher
    b>Cachexia is a wasting condition defined by skeletal muscle atrophy in the setting of systemic inflammation...
  48. Bessen R, Robinson C, Seelig D, Watschke C, Lowe D, Shearin H, et al. Transmission of chronic wasting disease identifies a prion strain causing cachexia and heart infection in hamsters. PLoS ONE. 2011;6:e28026 pubmed publisher
    ..a rodent model for CWD in Syrian golden hamsters that resemble key features of the disease in cervids including cachexia and infection of cardiac muscle...
  49. Jones A, Friedrich K, Rohm M, Schäfer M, Algire C, Kulozik P, et al. TSC22D4 is a molecular output of hepatic wasting metabolism. EMBO Mol Med. 2013;5:294-308 pubmed publisher
    ..As a molecular cachexia output pathway, hepatic levels of the transcription factor transforming growth factor beta 1-stimulated clone (..
  50. Mangner N, Matsuo Y, Schuler G, Adams V. Cachexia in chronic heart failure: endocrine determinants and treatment perspectives. Endocrine. 2013;43:253-65 pubmed publisher
    It is well documented in the current literature that chronic heart failure is often associated with cachexia, defined as involuntary weight loss of 5 % in 12 month or less...
  51. Prado C, Sawyer M, Ghosh S, Lieffers J, Esfandiari N, Antoun S, et al. Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential?. Am J Clin Nutr. 2013;98:1012-9 pubmed publisher
    Skeletal muscle wasting is considered the central feature of cachexia, but the potential for skeletal muscle anabolism in patients with advanced cancer is unproven.
  52. Nicolini A, Ferrari P, Masoni M, Fini M, Pagani S, Giampietro O, et al. Malnutrition, anorexia and cachexia in cancer patients: A mini-review on pathogenesis and treatment. Biomed Pharmacother. 2013;67:807-17 pubmed publisher
    Malnutrition, anorexia and cachexia are a common finding in cancer patients. They become more evident with tumor growth and spread. However, the mechanisms by which they are sustained often arise early in the history of cancer...
  53. Ries A, Trottenberg P, Elsner F, Stiel S, Haugen D, Kaasa S, et al. A systematic review on the role of fish oil for the treatment of cachexia in advanced cancer: an EPCRC cachexia guidelines project. Palliat Med. 2012;26:294-304 pubmed publisher
    The European Palliative Care Research Collaboration is developing clinical guidelines on cachexia in patients with advanced cancer...